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Background
Riociguat is the first oral, soluble guanylate cyclase sti-
mulator under review for the treatment of pulmonary
hypertension (PH), a progressive, ultimately fatal disease
[1-7]. This pooled analysis of two studies evaluated the
pharmacokinetics of riociguat and its metabolite M1
(BAY 60-4552) in individuals with and without renal
impairment. The safety and tolerability of riociguat were
also assessed.
Methods
Two non-randomized, non-blinded, observational studies
with group stratification were conducted in a single centre
in Germany, following Good Clinical Practice and relevant
industry guidelines [8,9]. Participants were assigned to one
of four renal function groups according to their creatinine
clearance (CLCR): group 1, CLCR > 80 mL/min; group 2,
CLCR 50–80 mL/min; group 3, CLCR 30–49 mL/min;
group 4, CLCR < 30 mL/min. In the first study, individuals
in group 4 received riociguat 0.5 mg; all other participants
in both studies received riociguat 1 mg (single tablet
doses). Pharmacokinetic parameters were assessed using
dense sampling.
Results
Sixty-three participants (40 men and 23 women; mean age,
61.3 years [range, 36–78 years]) completed the study and
were eligible for pharmacokinetic analysis. Riociguat was
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Table 1 Pharmacokinetic parameters of riociguat in healthy participants and in individuals with mild, moderate or
severe renal impairment
Parameter Group 1 (CRCL > 80 mL/min)
n = 16
Group 2 (CRCL 50–80 mL/min)
n = 15
Group 3 (CRCL 30–49 mL/min)
n = 16
Group 4a (CRCL < 30 mL/min)
n = 16
AUC, μg·h/L 245.7 (51) 347.5 (111) 499.0 (110) 523.0 (70.4)b




20.6 (56) 29.4 (126) 42.1 (109) 29.7 (102)
Cmax,norm, kg/
L
3.07 (17) 3.48 (25) 3.54 (30) 2.97 (40)
t½, h 6.19 (50) 10.1 (116) 11.4 (103) 9.52 (75)
aIn the first study, individuals with severe renal impairment (group 4) received riociguat 0.5 mg; all other participants in both studies received riociguat 1 mg.
bAUC and Cmax values shown for individuals with severe renal impairment (group 4) are taken from the second study (n = 8), in which individuals with severe
renal impairment received riociguat 1.0 mg.
Values are geometric means (percentage coefficient of variation). AUC, area under the plasma concentration–time curve from time 0 to infinity; AUCnorm, AUC
divided by dose per kilogram of body weight for total riociguat; Cmax, maximum concentration in plasma; Cmax,norm, Cmax divided by dose per kilogram of body
weight for total riociguat; t½, terminal elimination half-life for total riociguat.
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rapidly absorbed; median time to reach maximum concen-
tration in plasma (tmax) (Cmax) was 1 hour in all four
groups. Mean half-life of total riociguat was longer in
groups 2–4 (9.5–11.4 hours) than in group 1 (6.2 hours)
(Table 1), and renal clearance of riociguat decreased with
decreasing renal function. Mean exposure to total rioci-
guat (area under the concentration–time curve divided by
dose per kilogram of body weight [AUCnorm]) was 42.7–
104.3% higher in groups 2–4 than in group 1 (Table 1,
Figure 1). However, exposure was highly variable in groups
2–4 and the exposure ranges in all groups overlapped
(Figure 1). Exposure to riociguat did not increase strictly
in parallel with decreasing CLCR. Results for unbound rio-
ciguat and M1 were similar to those for total riociguat and
M1. No serious or severe adverse events were reported.
Headache was the most common drug-related adverse
event. No changes in safety or tolerability were detected
with decreasing CLCR. Riociguat Cmax and AUC ranges in
patients with renal impairment overlapped those pre-
viously observed in healthy volunteers and patients with
PH [2,3].
Conclusion
Exposure to riociguat was higher in individuals with renal
impairment (CLCR 15–80 mL/min) than in controls; par-
ticular care should be exercised during individual dose
titration in patients with renal impairment.
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